Growth Metrics

Summit Therapeutics (SMMT) Beginning Cash Balance (2022 - 2024)

Summit Therapeutics filings provide 3 years of Beginning Cash Balance readings, the most recent being $75.5 million for Q4 2024.

  • Quarterly Beginning Cash Balance changed N/A to $75.5 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $151.0 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $100.0 million for FY2024, 305.09% up from the prior year.
  • Beginning Cash Balance hit $75.5 million in Q4 2024 for Summit Therapeutics, roughly flat from $75.5 million in the prior quarter.
  • Across five years, Beginning Cash Balance topped out at $75.5 million in Q3 2024 and bottomed at $24.7 million in Q1 2023.
  • Average Beginning Cash Balance over 3 years is $50.2 million, with a median of $50.2 million recorded in 2022.